Matrix metalloproteinase 2-responsive micelle for siRNA delivery
Source abstract
Abstract
Systemic delivery of small interfering RNA (siRNA) into cancer cells remains the major obstacle to siRNA drug development. An ideal siRNA delivery vehicle for systemic administration should have long circulation time in blood, accumulate at tumor site, and sufficiently internalize into cancer cells for high-efficiency of gene silence. Herein, we report a core-shell Micelleplex delivery system that made from block copolymer bearing poly(ethylene glycol) (PEG), matrix metalloproteinase 2 (MMP-2)-degradable peptide PLG*LAG, cationic cell penetrating peptide polyarginine r9 and poly(ε-caprolactone) (PCL) for siRNA delivery. We show clear evidences in vitro and in vivo to prove that the micelle carrying siRNA can circulate enough time in blood, enrich accumulation at tumor sites, shed the PEG layer when triggered by tumor overexpressing MMP-2, and then the exposing cell penetrating peptide r9 enhanced cellular uptake of siRNA. Accordingly, this design strategy enhances the inhibition of breast tumor growth following systemic injection of this system carrying siRNA against Polo-like kinase 1, which demonstrating this Micelleplex can be a potential delivery system for systemic siRNA delivery in cancer therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (47)
Show source-provided references
1. Current prospects for RNA interference-based therapies10.1038/nrg2968 ↗
2. RNA-based therapeutics: current progress and future prospects10.1016/j.chembiol.2011.12.008 ↗
3. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR510.1073/pnas.232688199 ↗
4. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles10.1021/nn201397z ↗
5. RNAi-mediated gene silencing in non-human primates10.1038/nature04688 ↗
6. Rational design of cationic lipids for siRNA delivery10.1038/nbt.1602 ↗
7. Lipid-based nanotherapeutics for siRNA delivery10.1111/j.1365-2796.2009.02189.x ↗
8. In vivo delivery of RNAi with lipid-based nanoparticles10.1146/annurev-bioeng-071910-124709 ↗
9. Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy10.1016/j.jconrel.2012.05.015 ↗
10. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis10.1126/scitranslmed.3003601 ↗
11. Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers10.1021/nn204102q ↗
12. Magnetic silica spheres with large nanopores for nucleic acid adsorption and cellular uptake10.1016/j.biomaterials.2011.10.001 ↗
13. Star-branched amphiphilic PLA-b-PDMAEMA copolymers for co-delivery of miR-21 inhibitor and doxorubicin to treat glioma10.1016/j.biomaterials.2013.11.039 ↗
14. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors10.1016/j.biomaterials.2011.09.061 ↗
15. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery10.1016/j.biomaterials.2013.11.046 ↗
16. A mesoporous silica nanoparticle-PEI-fusogenic peptide system for siRNA delivery in cancer therapy10.1016/j.biomaterials.2012.10.072 ↗
17. Poly (ethylene glycol) in drug delivery: pros and cons as well as potential alternatives10.1002/anie.200902672 ↗
18. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review10.1016/S0168-3659(99)00248-5 ↗
19. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes10.1016/S0005-2736(01)00399-6 ↗
20. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles10.1078/0171-9335-00363 ↗
21. Redox/pH dual stimuli-responsive biodegradable nanohydrogels with varying responses to dithiothreitol and glutathione for controlled drug release10.1016/j.biomaterials.2012.05.062 ↗
22. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery10.1021/ja207150n ↗
23. RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system10.1016/j.jconrel.2010.01.009 ↗
24. Arginine-grafted bioreducible poly (disulfide amine) for gene delivery systems10.1016/j.biomaterials.2008.10.009 ↗
25. Matrix metalloproteinase responsive, proximity-activated polymeric nanoparticles for siRNA delivery10.1002/adfm.201202215 ↗
26. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting10.1021/nn300524f ↗
27. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid10.1016/j.biomaterials.2011.02.045 ↗
28. Matrix metalloproteinases: regulators of the tumor microenvironment10.1016/j.cell.2010.03.015 ↗
29. Tumor imaging by means of proteolytic activation of cell-penetrating peptides10.1073/pnas.0408191101 ↗
30. Tumor targeting and microenvironment-responsive nanoparticles for gene delivery10.1016/j.biomaterials.2013.03.043 ↗
31. Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery10.1021/nn204240b ↗
32. N-acetylgalactosamine functionalized mixed micellar nanoparticles for targeted delivery of siRNA to liver10.1016/j.jconrel.2012.12.017 ↗
33. Polymeric-micelle-based nanomedicine for siRNA delivery10.1002/ppsc.201200061 ↗
34. Surface charge switchable nanoparticles based on zwitterionic polymer for enhanced drug delivery to tumor10.1002/adma.201202296 ↗
35. Nanocarriers as an emerging platform for cancer therapy10.1038/nnano.2007.387 ↗
36. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits10.1016/S0378-5173(02)00703-2 ↗
37. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size
38. Self-assembly nanomicelles based on cationic mPEG-PLA-b-Polyarginine (R15) triblock copolymer for siRNA delivery10.1016/j.biomaterials.2012.05.067 ↗
39. Poly (oligo-d-arginine) with internal disulfide linkages as a cytoplasm-sensitive carrier for siRNA delivery10.1038/mt.2010.242 ↗
40. Potent and selective mechanism-based inhibition of gelatinases10.1021/ja001461n ↗
41. Sterically stabilized pH-sensitive liposomes intracellular delivery of aqueous contents and prolonged circulation in vivo10.1074/jbc.272.4.2382 ↗
42. A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy10.1016/j.biomaterials.2011.01.006 ↗
43. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells
44. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid10.1038/sj.gt.3302843 ↗
45. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice10.1172/JCI37515 ↗
46. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
47. Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia10.1021/nn200876f ↗